These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1115032)
1. Mast cells and myelofibrosis. Udoji WC; Razavi SA Am J Clin Pathol; 1975 Feb; 63(2):203-9. PubMed ID: 1115032 [TBL] [Abstract][Full Text] [Related]
2. The stromal composition of mast cell aggregates in systemic mastocytosis. Chiu A; Nanaji NM; Czader M; Gheorghe G; Knowles DM; Chadburn A; Orazi A Mod Pathol; 2009 Jul; 22(7):857-65. PubMed ID: 19396155 [TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow. Nakayama S; Yokote T; Hiraoka N; Akioka T; Nishiwaki U; Miyoshi T; Iwaki K; Fumimoto A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M Hum Pathol; 2017 Apr; 62():180-186. PubMed ID: 28159675 [TBL] [Abstract][Full Text] [Related]
4. Agnogenic myeloid metaplasia. Block M Rev Bras Pesqui Med Biol; 1974; 7(2):185-95. PubMed ID: 4527643 [No Abstract] [Full Text] [Related]
5. Mast cell leukaemia: evidence for bone marrow origin of the pathological clone. Dalton R; Chan L; Batten E; Eridani S Br J Haematol; 1986 Oct; 64(2):397-406. PubMed ID: 3096368 [TBL] [Abstract][Full Text] [Related]
6. Assessment of bone marrow and splenic erythropoiesis in myelofibrosis. Ferrant A; Rodhain J; Cauwe F; Cogneau M; Beckers C; Michaux JL; Verwilghen R; Sokal G Scand J Haematol; 1982 Nov; 29(5):373-80. PubMed ID: 7156888 [TBL] [Abstract][Full Text] [Related]
7. Ultrasonic characterization of splenic tissue in myelofibrosis: further evidence for reversal of fibrosis with chemotherapy. Manoharan A; Chen CF; Wilson LS; Griffiths KA; Robinson DE Eur J Haematol; 1988 Feb; 40(2):149-54. PubMed ID: 3278929 [TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological features of primary myelofibrosis from onset to blast transformation: report of two cases. Yonemitsu H; Kanazawa S; Kondo H; Okuda K Nihon Ketsueki Gakkai Zasshi; 1985 Feb; 48(1):64-71. PubMed ID: 4003013 [No Abstract] [Full Text] [Related]
16. [Case of idiopathic myelofibrosis with a prolonged and unusual course]. Klimova NF; Popov VM Probl Gematol Pereliv Krovi; 1972 Aug; 17(8):50-3. PubMed ID: 4653728 [No Abstract] [Full Text] [Related]
17. Different composition of the erythropoietic tissue in bone marrow, spleen and liver in myelofibrosis. Sjögren U Acta Haematol; 1978; 59(4):231-6. PubMed ID: 417545 [TBL] [Abstract][Full Text] [Related]
19. CD34+ progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue. Thiele J; Kvasnicka HM; Czieslick C Ann Hematol; 2002 Feb; 81(2):86-9. PubMed ID: 11907788 [TBL] [Abstract][Full Text] [Related]
20. Erythroid hypoplasia in myelofibrosis: a feature associated with blastic transformation. Bentley SA; Murray KH; Lewis SM; Roberts PD Br J Haematol; 1977 May; 36(1):41-7. PubMed ID: 871424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]